MEDICUS PHARMA LTD. Cash and Cash Equivalents, Fair Value Disclosure
MEDICUS PHARMA LTD. (MDCX) had Cash and Cash Equivalents, Fair Value Disclosure of $25.19 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-08-12
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $25.19M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $6.37M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $8.71M.
- 2024-12-31: Cash and Cash Equivalents, Fair Value Disclosure $4.16M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $25.19M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $6.37M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $8.71M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $4.16M 10-K · filed 2026-03-25 |
| 2023-12-31 | $1.72M 10-K · filed 2025-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B |